

January 22, 2016



OPKO's GeneDx to Present at Personalized Medicine World Conference

MIAMI--(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) announced today that Marc D. Grodman, MD, Chief Executive Officer of its BioReference/GeneDx subsidiaries, will speak at this year's [Personalized Medicine World Conference, Silicon Valley](#). Dr. Grodman's Presentation, titled "New Model of Clinical Genomics Collaboration", will highlight a unique partnership between GeneDx and health systems to provide a complete genomic solution that facilitates improved patient care, education, research opportunities and commercial R&D collaborations.

As part of the "New Approaches in Cancer Dx" track, Dr. Grodman is scheduled to present on January 26th at 1:00 p.m. Pacific Time in Track 3 of the conference. Details on his talk can be found at <http://2016sv.pmwintl.com/bio-marc-grodman>.

The Personalized Medicine World Conference is an independent conference, co-hosted with Stanford Health Care and UCSF, that brings together experts across healthcare and biotechnology sectors to help further the adoption of personalized medicine in the clinic. This year's Silicon Valley conference will be held on January 26th through the 27th at the Computer History Museum in Mountain View, California.

About OPKO Health, Inc.

OPKO Health, Inc. is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 420-person sales force to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros®1 in-office immunoassay platform. Our pharmaceutical business features Rayaldee™, a treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (March 29, 2016 PDUFA date) and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner Tesaro, IV formulation in Phase 3). Our biologics business includes hGH-CTP, a once-weekly human growth hormone injection (in Phase 3 and partnered with Pfizer), and a long-acting Factor VIIa drug for hemophilia (entering Phase 2a). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information is available at www.opko.com.

About BioReference and GeneDx

GeneDx and its parent company BioReference Laboratories Inc. are members of the OPKO Health, Inc. (NYSE: OPK) group of companies. BioReference is the third largest clinical laboratory in the US and is a leader in technological innovation in the industry. GeneDx is a world leader in Genomics with an acknowledged expertise in rare and ultra rare genetic disorders, as well as one of the broadest menus of sequencing services available among

commercial laboratories. GeneDx performs more clinical Whole Exome Sequencing tests than any other diagnostic lab in the world. The GeneDx mission is to make clinical testing affordable and available to people with rare genetic conditions and their families. GeneDx provides testing to patients and their families in more than 55 countries. To learn more, please visit www.bioreference.com and www.genedx.com.

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20160122005245/en/>

OPKO Health, Inc.

Carly Erickson, 202-600-4558

cerickson@mww.com

or

Tara Mackay, 305-575-4100

Investor Relations

or

Media

Rooney & Associates

Terry Rooney, 212-223-0689

trooney@rooneyco.com

or

Marion Janic, 212-223-4017

mjanic@rooneyco.com

or

Investors

LHA

Anne Marie Fields, 212-838-3777

afields@lhai.com

or

Bruce Voss, 310-691-7100

bvoss@lhai.com

Source: OPKO Health, Inc.